Clinical Trials Logo

Clinical Trial Summary

High frequency repetitive transcranial magnetic stimulation (HF-rTMS) over dorsolateral prefrontal cortex (DLPFC) could correct defective executive functions over the hyperactive reward circuit through the meso-fronto-limbic connections. The restored cortical inhibitory control over compulsive alcohol use, could improve abstinence after withdrawal. The goal of this study is to evaluate the efficacy of HF-rTMS over DLPFC in AUD patients with executive dysfunction after withdrawal.


Clinical Trial Description

PARTICIPANTS: Participants with AUD (moderate to mild according to Alcohol Dependance Scale) with executive dysfunctions will be randomized. DESIGN: This study is a multicenter pilot double blind randomized controlled trial. After at least seven days of alcohol residential detoxification, executive dysfunctions's participants will be tested. 64 of them with executive dysfunctions will be randomized either in the active rTMS group or in the sham rTMS group. TMS will be performed during hospitalisation over 10 days. rTMS are proposed as an add on to the usual treatment. INTERVENTION: 20 rTMS (twice a day) will be performed 10 consecutive working days. The target of the rTMS will be the DLPFC (left side in the morning, right side in the afternoon). During each rTMS sessions (active and sham), alcohol related pictures from the Geneva Appetitive alcohol Pictures will be presented.In the active arm, rTMS will be performed with high frequency (20hz, 1500 pulses per session, 110% of motor threshold).In the control group, sham rTMS will be performed. Participants will be follow up to three months after the end of rTMS treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04997330
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Fanny LEVY, Docteur
Phone 01.42.16.28.94
Email fanny.levy@aphp.fr
Status Not yet recruiting
Phase N/A
Start date September 2021
Completion date July 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03916939 - Osteopathic Treatment to Alcohol Withdrawal Syndrome N/A
Completed NCT04858490 - Remote Treatment of Alcohol Withdrawal N/A
Recruiting NCT04876443 - Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
Completed NCT05131334 - Auricular Vagal Stimulation in Alcohol Craving N/A
Completed NCT02349477 - Gabapentin for Alcohol Relapse Prevention Phase 2
Terminated NCT01937364 - Preventing Alcohol Withdrawal With Oral Baclofen Phase 2
Completed NCT05393544 - Digitally Assisted Recovery Coach N/A
Completed NCT00523185 - A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal N/A
Completed NCT01573052 - Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal Phase 4
Enrolling by invitation NCT06173973 - Effects of Ketone Supplementation on Acute Alcohol Withdrawal Phase 2/Phase 3
Active, not recruiting NCT03737864 - NCARE, Transition to Recovery N/A
Recruiting NCT03878225 - Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans? N/A
Terminated NCT03586089 - Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome N/A
Recruiting NCT04156464 - Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit Phase 4
Completed NCT02251912 - Oxytocin Treatment of Alcohol Dependence Phase 2
Completed NCT02202148 - Liver Stiffness Measurement in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal N/A
Completed NCT01212185 - Oxytocin Treatment of Alcohol Withdrawal Phase 1
Recruiting NCT04793685 - Prazosin for Alcohol Use Disorder With Withdrawal Symptoms Phase 1/Phase 2
Withdrawn NCT04159909 - Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal N/A
Completed NCT05563350 - Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms